multiple myeloma

     

Select
Display
Trial Studied trt Control trt patientstagsNCTROB Result

All mechanism

not classified
CLARIONcarfilzomibNCT01818752 -
NCT01863550carfilzomibNCT01863550 -
ENDEAVOR ongoing carfilzomib NCT01568866 ongoing
ARROW ongoing carfilzomib NCT02412878 ongoing
FOCUS ongoing carfilzomib NCT01302392 ongoing
ELOQUENT - 1 Elotuzumab Lenalidomide Dexamethasone Lenalidomide + Dexamethasone NCT01335399 -
ELOQUENT - 2Elotuzumab Lenalidomide Dexamethasone Lenalidomide + Dexamethasone NCT01239797 -
Tourmaline-MM1 ongoing ixazomib+ Lenalidomide + DexamethasoneLenalidomide + DexamethasoneNCT01564537 ongoing
MRC Myeloma IXCTDaMPISRCTN68454111 -
MM-015MPR+RMPNCT00405756 -
IFM 01/01MPTMP -
IFM 99/06MPTMPNCT00367185 -
NCT01274403MPTMPNCT01274403 -
GIMEMAMPT+TMPNCT00232934 -
HOVON 49MPT+TMPISRCTN90692740 -
NMSGMPT+TMP -
TMSGMPT+TMPNCT00934154 -
VISTAVMPMPNCT00111319 -
FIRST Rd ou Rd18MPTNCT00689936 -
EIA06 (NCT00602641)MPR+RMPT+TNCT00602641 -
NR 1997PCAB+IFN-2aPCAB -
ASPIRE, 2015carfilzomib placebo (on top lenalidomide and dexamethasone)NCT01080391suggesting
ELOQUENT 2, 2015elotuzumab placebo (on top lenalidomide and dexamethasone)NCT01239797negative
NR 2013MPR + CPRRd -
NCT00911859VMP + siltuximabVMPNCT00911859 -
NR 2010VMPT+VTVMP -

immune checkpoint inhibition

nivolumab
CheckMate 602 ongoing Nivolumab, Elotuzumab, Pomalidomide, dexaMNCT02726581Risk of bias ongoing
pembrolizumab
KEYNOTE-183 ongoing pembrolizumabrrMMNCT02576977Risk of bias ongoing
KEYNOTE-185 ongoing pembrolizumab, lenalidomide, dexametahsonelenalidomide, dexamethasonenot eligible for ASCTNCT02579863Risk of bias ongoing